Key transcriptional effectors of the pancreatic acinar phenotype and oncogenic transformation
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0291512 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Ana Azevedo-Pouly und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and the Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, …. Hauptthemen laut MEDLINE: Pancreas, Exocrine, Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Proper maintenance of mature cellular phenotypes is essential for stable physiology, suppression of disease states, and resistance to oncogenic transformation. We describe the transcriptional regulatory roles of four key DNA-binding transcription factors (Ptf1a, Nr5a2, Foxa2 and Gata4) that sit at the top of a regulatory hierarchy controlling all aspects of a highly differentiated cell-type–the mature pancreatic acinar cell (PAC). Selective inactivation of Ptf1a , Nr5a2 , Foxa2 and Gata4 individually in mouse adult PACs rapidly altered the transcriptome and differentiation status of PACs. The changes most emphatically included transcription of the genes for the secretory digestive enzymes (which conscript more than 90% of acinar cell protein synthesis), a potent anabolic metabolism that provides the energy and materials for protein synthesis, suppressed and properly balanced cellular replication, and susceptibility to transformation by oncogenic Kras G12D . The simultaneous inactivation of Foxa2 and Gata4 caused a greater-than-additive disruption of gene expression and uncovered their collaboration to maintain Ptf1a expression and control PAC replication. A measure of PAC dedifferentiation ranked the effects of the conditional knockouts as Foxa2+Gata4 > Ptf1a > Nr5a2 > Foxa2 > Gata4. Whereas the loss of Ptf1a or Nr5a2 greatly accelerated Kras-mediated transformation of mature acinar cells in vivo, the absence of Foxa2, Gata4, or Foxa2+Gata4 together blocked transformation completely, despite extensive dedifferentiation. A lack of correlation between PAC dedifferentiation and sensitivity to oncogenic Kras G12D negates the simple proposition that the level of differentiation determines acinar cell resistance to transformation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and the Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
- Department of Human Genetics, University of Utah, Salt Lake City, Utah, United States of America.
ORCID-Profile: Ana Azevedo-Pouly, Raymond J MacDonald
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Azevedo-Pouly, A., Hale, M. A., Swift, G. H., Hoang, C. Q., Deering, T. G., Xue, J., Wilkie, T. M., Murtaugh, L. C., & MacDonald, R. J. (2023). Key transcriptional effectors of the pancreatic acinar phenotype and oncogenic transformation. PLOS ONE. https://doi.org/10.1371/journal.pone.0291512
Vancouver
Azevedo-Pouly A, Hale MA, Swift GH, Hoang CQ, Deering TG, Xue J, et al. Key transcriptional effectors of the pancreatic acinar phenotype and oncogenic transformation. PLOS ONE. 2023. doi:10.1371/journal.pone.0291512
BibTeX
@article{AzevedoPouly2023,
author = {Azevedo-Pouly, Ana and Hale, Michael A and Swift, Galvin H and Hoang, Chinh Q and Deering, Tye G and Xue, Jumin and Wilkie, Thomas M and Murtaugh, L Charles and MacDonald, Raymond J},
title = {Key transcriptional effectors of the pancreatic acinar phenotype and oncogenic transformation},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0291512}
}
EUVIMED